Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 6,227	$ 15,045
Prepaid expenses and other current assets	1,707	1,381
Total Current Assets	7,934	16,426
Property and equipment, net	174	367
Right-of-Use Asset	279	419
Deposits and other assets	23	23
Total Assets	8,410	17,235
Current Liabilities:
Accounts payable	886	2,315
Accrued expenses	925	1,776
Accrued employee benefits	868	935
Lease liability	287	249
Total Current Liabilities	2,966	5,275
Lease liability - Long term	186	473
Total Liabilities	3,152	5,748
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding	12,798	12,544
Stockholders' Deficit:
Series B convertible preferred stock, $0.0001 par value; 10,000,000 shares authorized, 3,973 issued and outstanding at December 31,2020 and 7,638 issued and outstanding at December 31, 2020	2,477	4,761
Common stock, $0.001 par value; 200,000,000 shares authorized, 29,252,253 issued and 29,249,925 outstanding at December 31,2020 and 16,808,758 issued and 16,806,430 outstanding at December 31,2019	29	17
Additional paid-in capital	240,821	232,580
Accumulated deficit	(248,094)	(235,537)
Total Synthetic Biologics, Inc. and Subsidiaries (Deficit) Equity	(4,767)	1,821
Non-controlling interest	(2,773)	(2,878)
Total Stockholders' Deficit	(7,540)	(1,057)
Total Liabilities and Stockholders' Deficit	$ 8,410	$ 17,235